Jade Biosciences

Jade Biosciences announces sale of 10 million common shares at $15.00 per share, raising about $150 million before fees and representing a discount of roughly 14.7% to the prior day’s close. The announcement and a 30-day greenshoe option for up to 1.5 million additional shares weighed on premarket trading and led to a roughly 9.3% drop. Jefferies, TD Cowen and UBS are acting as bookrunners; proceeds are intended to fund clinical and preclinical studies and production. A weak market environment amplified selling pressure, but the company stresses the move is to advance the JADE101 pipeline and does not signal financial distress. » More on de.investing.com

Jade Biosciences is offering 10 million common shares at $15.00 per share and expects gross proceeds of $150 million before fees. The offering price is below the current market price; closing is expected on June 5, 2026, and the underwriters have a 30-day option to purchase up to 1.5 million additional shares. Net proceeds are intended to fund clinical trials, preclinical research, manufacturing, R&D, and for working capital and general corporate purposes. » More on de.investing.com

Jade Biosciences' stock fell about 6.5% in after-hours trading after the company announced a guaranteed public offering of common stock. Certain investors will be offered common shares or pre-funded warrants, with all securities to be sold by Jade itself and the bookrunning banks granted a 30-day option to purchase up to 15% of the offered securities. Net proceeds are intended to fund clinical and preclinical studies, manufacturing, research and development, and working capital. Jefferies, TD Cowen, UBS and LifeSci Capital are acting as bookrunners, BTIG as lead manager; closing and final terms remain uncertain. » More on de.investing.com